Uncategorized

D-Wave’s strongest-ever cash position is funding acquisitions, technology development and manufacturing expansion while its system sales pipeline has doubled, even as the company remains EBITDA-negative. read more

Eli Lilly’s orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight the company’s growth strength. Latest Ratings for LLY Date Firm Action From To Feb 2022 Morgan Stanley Maintains Overweight Feb 2022 Mizuho Maintains Buy Jan 2022 Morgan Stanley Maintains Overweight View More Analyst Ratings for…

Tech-saturated Nasdaq 100 ETFs hit record highs despite U.S. tariff hike. Leading the pack were Invesco’s QQQ, QQQM and QQQE. Strong performance driven by confident investors and stable big-cap techs. read more

Celsius’s Q2 beat driven by Alani Nu integration and zero-sugar innovation sets the stage for accelerated revenue growth and EBITDA upside. Latest Ratings for CELH Date Firm Action From To Nov 2021 Stifel Initiates Coverage On Buy Nov 2021 B. Riley Securities Maintains Buy Nov 2021 Credit Suisse Downgrades Outperform Neutral View More Analyst Ratings…

Iamgold Corp (NYSE:IAG) reported Q2 results, including successful ramp up of Cote Gold mine. Strategic priorities and financial performance discussed. read more